VISTAGEN THERAPEUTICS, INC. Capitalized Contract Cost, Net, Current
VISTAGEN THERAPEUTICS, INC. (VTGN) had Capitalized Contract Cost, Net, Current of $67.10 thousand as of 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:CapitalizedContractCostNetCurrent · last filed 2023-08-10
- 2023-06-30: Capitalized Contract Cost, Net, Current $67.10K.
- 2023-03-31: Capitalized Contract Cost, Net, Current $67.10K.
- 2022-12-31: Capitalized Contract Cost, Net, Current $67.00K.
- 2022-09-30: Capitalized Contract Cost, Net, Current $67.00K.
| Period end | Capitalized Contract Cost, Net, Current |
|---|---|
| 2023-06-30 | $67.10K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $67.10K 10-Q · filed 2023-08-10 |
| 2022-12-31 | $67.00K 10-Q · filed 2023-02-07 |
| 2022-09-30 | $67.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $116.90K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $116.90K 10-Q · filed 2023-02-07 |
| 2021-12-31 | $133.50K 10-Q · filed 2022-02-10 |
| 2021-09-30 | $133.50K 10-Q · filed 2021-11-10 |
| 2021-03-31 | $133.50K 10-Q · filed 2022-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |